Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan

-- The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population -- -- First-in-human clinical trial of Lomecel-B™ in Japan --... | April 19, 2023

Related Keywords

United States ,Miami ,Florida ,Tokyo ,Japan ,Nagoya ,Aichi ,Japanese ,Hidenori Arai ,Japan Pharmaceuticals ,Devices Agency ,Globenewswire Inc ,National Center ,Juntendo University Hospital ,Longeveron Inc ,Exchange Commission ,Longeveron Or Company ,Stern Ir Inc ,Company Quarterly Reports On Form ,Nasdaq ,Aging Related Frailty ,Japanese Aging Related Frailty ,Wa El Hashad ,Chief Executive ,Regenerative Medicine ,University Hospital ,Related Frailty ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Longeveron Inc Stock Exchange ,News ,Information ,Press Release ,The ,Primary ,Objective ,Us ,O ,Valuate ,Safety ,F ,Elderly ,Population ,Linical ,Trial ,Apan Lgvn Us54303l1044 ,